Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant env trimers in HIV vaccination

Bioconjugate Chemistry

Volumn 25, Issue 8, 2014, Pages 1470-1478

  Pejawar Gaddy, Sharmila ^a,b   Kovacs, James M ^c   Barouch, Dan H ^b,d   Chen, Bing ^c   Irvine, Darrell J ^a,b,e  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DISEASES; EPITOPES; IMMUNIZATION; LIPIDS; NANOCAPSULES; T-CELLS; VACCINES; VIRUSES;

ANTIBODIES RESPONSE; DELIVERY VEHICLE; FOLLICULAR HELPER T CELLS; FUNCTIONALIZED LIPIDS; GLYCOSYLATED; HIS-TAG; LIPID NANOCAPSULES; T-CELL RESPONSE; TRIMER STRUCTURE; VIRUS STRAINS;

OLIGOMERS;

ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERBILAYER CROSSLINKED MULTILAMELLAR VESICLE; NANOCAPSULE; PHOSPHORYL LIPID A; RECOMBINANT GLYCOPROTEIN GP 140 VACCINE; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; RECOMBINANT PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LIPID COMPOSITION; MOUSE; NANOENCAPSULATION; NONHUMAN; PROTEIN FOLDING; SURFACE PROPERTY; VACCINATION; ANIMAL; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MOLECULAR WEIGHT; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE;

ANIMALS; ANTIGENS, VIRAL; DRUG CARRIERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV; IMMUNITY, HUMORAL; LIPIDS; MICE; MOLECULAR WEIGHT; NANOCAPSULES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; VACCINATION;

EID: 84906348394     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc5002246     Document Type: Article

References (40)

1. Demberg, T. and Robert-Guroff, M. (2012) Controlling the HIV/AIDS epidemic: current status and global challenges Front Immunol 3, 250
2. Harrison, S. C. (2008) Viral membrane fusion Nat. Struct. Mol. Biol. 15, 690-8
3. Clapham, P. R. and Lu, S. (2011) Vaccinology: precisely tuned antibodies nab HIV Nature 477, 416-7
4. Blumenthal, R., Durell, S., and Viard, M. (2012) HIV entry and envelope glycoprotein-mediated fusion J. Biol. Chem. 287, 40841-9
5. van Gils, M. J. and Sanders, R. W. (2013) Broadly neutralizing antibodies against HIV-1: templates for a vaccine Virology 435, 46-56
6. Gilbert, P., Wang, M., Wrin, T., Petropoulos, C., Gurwith, M., Sinangil, F., D'Souza, P., Rodriguez-Chavez, I. R., DeCamp, A., Giganti, M., Berman, P. W., Self, S. G., and Montefiori, D. C. (2010) Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine J. Infect. Dis. 202, 595-605
7. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A., and Wyatt, R. T. (2004) HIV vaccine design and the neutralizing antibody problem Nat. Immunol. 5, 233-6
8. Kovacs, J. M., Nkolola, J. P., Peng, H., Cheung, A., Perry, J., Miller, C. A., Seaman, M. S., Barouch, D. H., and Chen, B. (2012) HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120 Proc. Natl. Acad. Sci. U. S. A. 109, 12111-6
9. Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., Lehrman, J. K., Priddy, F. H., Olsen, O. A., Frey, S. M., Hammond, P. W., Investigators, P. G. P., Kaminsky, S., Zamb, T., Moyle, M., Koff, W. C., Poignard, P., and Burton, D. R. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326, 285-9
10. Beddows, S., Schulke, N., Kirschner, M., Barnes, K., Franti, M., Michael, E., Ketas, T., Sanders, R. W., Maddon, P. J., Olson, W. C., and Moore, J. P. (2005) Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 J. Virol. 79, 8812-27
11. Earl, P. L., Sugiura, W., Montefiori, D. C., Broder, C. C., Lee, S. A., Wild, C., Lifson, J., and Moss, B. (2001) Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140 J. Virol. 75, 645-53
12. Frey, G., Peng, H., Rits-Volloch, S., Morelli, M., Cheng, Y., and Chen, B. (2008) A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies Proc. Natl. Acad. Sci. U. S. A. 105, 3739-44
13. Kang, Y. K., Andjelic, S., Binley, J. M., Crooks, E. T., Franti, M., Iyer, S. P., Donovan, G. P., Dey, A. K., Zhu, P., Roux, K. H., Durso, R. J., Parsons, T. F., Maddon, P. J., Moore, J. P., and Olson, W. C. (2009) Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 Vaccine 27, 5120-32
14. Nkolola, J. P., Peng, H., Settembre, E. C., Freeman, M., Grandpre, L. E., Devoy, C., Lynch, D. M., La Porte, A., Simmons, N. L., Bradley, R., Montefiori, D. C., Seaman, M. S., Chen, B., and Barouch, D. H. (2010) Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs J. Virol. 84, 3270-9
15. Yang, X., Wyatt, R., and Sodroski, J. (2001) Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers J. Virol. 75, 1165
16. Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., and Bramwell, V. W. (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens Int. J. Pharm. 364, 272-80
17. Irvine, D. J., Swartz, M. A., and Szeto, G. L. (2013) Engineering synthetic vaccines using cues from natural immunity Nat. Mater. 12, 978-90
18. Shen, H., Ackerman, A. L., Cody, V., Giodini, A., Hinson, E. R., Cresswell, P., Edelson, R. L., Saltzman, W. M., and Hanlon, D. J. (2006) Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles Immunology 117, 78-88
19. Moon, J. J., Suh, H., Li, A. V., Ockenhouse, C. F., Yadava, A., and Irvine, D. J. (2012) Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction Proc. Natl. Acad. Sci. U. S. A. 109, 1080-5
20. Henriksen-Lacey, M., Christensen, D., Bramwell, V. W., Lindenstrom, T., Agger, E. M., Andersen, P., and Perrie, Y. (2011) Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses Mol. Pharm. 8, 153-61
21. Bachmann, M. F. and Jennings, G. T. (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10, 787-796
22. Li, A. V., Moon, J. J., Abraham, W., Suh, H., Elkhader, J., Seidman, M. A., Yen, M., Im, E. J., Foley, M. H., Barouch, D. H., and Irvine, D. J. (2013) Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination Sci. Transl. Med. 5, 204ra130
23. Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Um, S. H., Khant, H., Goodwin, J. T., Ramos, J., Chiu, W., and Irvine, D. J. (2011) Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses Nat. Mater. 10, 243-51
24. Scott, E. A., Stano, A., Gillard, M., Maio-Liu, A. C., Swartz, M. A., and Hubbell, J. A. (2012) Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes Biomaterials 33, 6211-6219
25. Pihlgren, M., Silva, A. B., Madani, R., Giriens, V., Waeckerle-Men, Y., Fettelschoss, A., Hickman, D. T., Lopez-Deber, M. P., Ndao, D. M., Vukicevic, M., Buccarello, A. L., Gafner, V., Chuard, N., Reis, P., Piorkowska, K., Pfeifer, A., Kundig, T. M., Muhs, A., and Johansen, P. (2013) TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice Blood 121, 85-94
26. Bal, S. M., Hortensius, S., Ding, Z., Jiskoot, W., and Bouwstra, J. A. (2011) Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination Vaccine 29, 1045-52
27. Bershteyn, A., Hanson, M. C., Crespo, M. P., Moon, J. J., Li, A. V., Suh, H., and Irvine, D. J. (2012) Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine J. Controlled Release 157, 354-65
28. Chikh, G. G., Li, W. M., Schutze-Redelmeier, M.-P., Meunier, J.-C., and Bally, M. B. (2002) Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids Biochim. Biophys. Acta 1567, 204-12
29. van Broekhoven, C. L. and Altin, J. G. (2005) The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells Biochim. Biophys. Acta 1716, 104-16
30. Watson, D. S., Platt, V. M., Cao, L., Venditto, V. J., and Szoka, F. C., Jr. (2011) Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice Clin. Vaccine Immunol. 18, 289-97
31. Kwong, P. D., Mascola, J. R., and Nabel, G. J. (2011) Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1 Cold Spring Harbor Perspect. Med. 1, a007278
32. Gonzalez, N., Alvarez, A., and Alcami, J. (2010) Broadly neutralizing antibodies and their significance for HIV-1 vaccines Current HIV Research 8, 602-12
33. Pantophlet, R. and Burton, D. R. (2006) GP120: target for neutralizing HIV-1 antibodies Annu. Rev. Immunol. 24, 739-69
34. Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., Alam, S. M., Wang, T., Yang, Y., Zhang, B., Migueles, S. A., Wyatt, R., Haynes, B. F., Kwong, P. D., Mascola, J. R., and Connors, M. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Nature 491, 406-12
35. Beddows, S., Franti, M., Dey, A. K., Kirschner, M., Iyer, S. P., Fisch, D. C., Ketas, T., Yuste, E., Desrosiers, R. C., Klasse, P. J., Maddon, P. J., Olson, W. C., and Moore, J. P. (2007) A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120 Virology 360, 329-40
36. Kim, M., Qiao, Z. S., Montefiori, D. C., Haynes, B. F., Reinherz, E. L., and Liao, H. X. (2005) Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies AIDS Res. Hum. Retroviruses 21, 58-67
37. Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., and Hubbell, J. A. (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 25, 1159-64
38. Masek, J., Bartheldyova, E., Turanek-Knotigova, P., Skrabalova, M., Korvasova, Z., Plockova, J., Koudelka, S., Skodova, P., Kulich, P., Krupka, M., Zachova, K., Czernekova, L., Horynova, M., Kratochvilova, I., Miller, A. D., Zyka, D., Michalek, J., Vrbkova, J., Sebela, M., Ledvina, M., Raska, M., and Turanek, J. (2011) Metallochelating liposomes with associated lipophilised norAbuMDP as biocompatible platform for construction of vaccines with recombinant His-tagged antigens: preparation, structural study and immune response towards rHsp90 J. Controlled Release 151, 193-201
39. Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., and Mitchell, T. C. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4 Science 316, 1628-32
40. Guy, B. (2007) The perfect mix: recent progress in adjuvant research Nat. Rev. Microbiol. 5, 505-17